July 3, 2022

autosankauf-emsdetten.de

WEBSITE NEWS UPDATE

Glucagon-like peptide-1 receptor agonist use may up risk for gallbladder, biliary diseases

2 min read

Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medicine.

Liyun He, from the Peking Union Medical College Hospital in China, and colleagues conducted a systematic review of randomized controlled trials (RCTs) comparing the use of GLP-1 RA drugs with placebo or with non-GLP-1 RA drugs in adults to examine the association with gallbladder and biliary diseases. Data from 76 RCTs with 103,371 patients were included in the meta-analysis.

The researchers found that randomization to GLP-1 RA treatment among all included trials was associated with increased risks for gallbladder or biliary diseases (pooled relative risk [RR], 1.37), specifically cholelithiasis, cholecystitis, and biliary disease (RRs, 1.27, 1.36, and 1.55, respectively). GLP-1 RA use was associated with an elevated risk for gallbladder or biliary diseases in trials for weight loss (13 trials; RR, 2.29) and for type 2 diabetes and other diseases (63 trials; RR, 1.27). For all included trials, the risks for gallbladder or biliary diseases were higher with higher doses of GLP-1 RA use versus lower doses and for longer versus shorter duration of use.

“Physicians should be concerned about the increased risk of gallbladder or biliary disease associated with GLP-1 RA use, especially at the higher doses recommended for weight loss,” the authors write.


Liraglutide ups risk for gallbladder, biliary tract events


More information:
Liyun He et al, Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases, JAMA Internal Medicine (2022). DOI: 10.1001/jamainternmed.2022.0338

See also  Dad with Alzheimer’s brought ‘back to life’by his favourite songs

Shanzay Haider et al, Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?, JAMA Internal Medicine (2022). DOI: 10.1001/jamainternmed.2022.0335

© 2022 HealthDay. All rights reserved.

Citation:
Glucagon-like peptide-1 receptor agonist use may up risk for gallbladder, biliary diseases (2022, March 31)
retrieved 1 April 2022
from https://medicalxpress.com/news/2022-03-glucagon-like-peptide-receptor-agonist-gallbladder.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Copyright © All rights reserved. | Newsphere by AF themes.